BEIJING – EOC Pharmaceutical Group, of Shanghai, completed a series C financing round, bagging $71 million to advance its lead programs EOC-103 and EOC-315 for breast and gastric cancers. The round was led by Hangzhou Tigermed Consulting Co. Ltd. and its affiliated funds, TF Capital and Yingke PE. Hanne Capital and Everest Venture Capital also participated in the round. In 2017, EOC raised $32 million in a series B round. All funding participants are China-based.
Menlo Park, Calif.-based Akoya Biosciences Inc. has scooped up $50 million in financing, with an eye toward growing via the expansion of commercial and operational resources and continuing product development activities around its platforms for spatial biology.
Tumor-agnostic therapy developer Black Diamond Therapeutics Inc. has completed an oversubscribed series C financing of $85 million. The Cambridge, Mass.-based company said proceeds will help it advance candidates targeting oncogenic driver mutations of the ErbB kinases in EGFR and HER2, starting with a combined phase I/II trial of its most advanced candidate next year.
DUBLIN – 4Teen4 Pharmaceuticals GmbH raised €6.9 million (US$7.7 million) in a series A round to take procizumab, a first-in-class inhibitor of circulating dipeptidyl-peptidase 3 (cDPP3), into clinical trials for patients with cardiogenic shock.
Civetta Therapeutics LLC will take a $53 million series A to advance its platform and programs based on beta-propeller proteins that mediate protein-to-protein interactions. Those proteins can become involved in cancers, neurodegeneration and metabolic disorders, with oncology being the company’s initial focus.
BEIJING – Chengdu-based Sichuan Clover Biopharmaceuticals Inc. closed a series B financing round to inject another $43 million into its drug development and manufacturing operations, with a focus on biologic candidate SCB-313, developed with its Trimer-Tag technology platform.